Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2013
11/20/2013EP2663304A1 Combination therapy
11/20/2013EP2663303A1 Anticancer therapy with dual aurora kinase / mek inhibitors
11/20/2013EP2663302A1 Use of simalikalactone e as an anticancer agent
11/20/2013EP2663301A1 Phosphaplatins having anti-angiogenic, anti-metastatic, and pro-apoptotic properties and uses thereof
11/20/2013EP2663300A1 Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
11/20/2013EP2663299A1 Melatonin and an antimicrobial or antibacterial agent for the treatment of acne
11/20/2013EP2663298A1 Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
11/20/2013EP2663297A2 Methods and compositions for protection of cells and tissues from computed tomography radiation
11/20/2013EP2663296A1 Donepezil transdermal patch
11/20/2013EP2663295A2 Highly concentrated liquid acetaminophen solutions
11/20/2013EP2663292A2 Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
11/20/2013EP2663289A2 Cefpodoxime proxetil formulations comprising taste regulating agent
11/20/2013EP2663287A1 Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
11/20/2013EP2663286A1 Preventive effect of citrulline on the spontaneous development of tumors
11/20/2013EP2663285A2 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof
11/20/2013EP2663284A1 Implant comprising a core and a tube encasing the core
11/20/2013EP2663283A1 High drug load tablet formulation of brivanib alaninate
11/20/2013EP2663281A1 Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
11/20/2013EP2663189A1 Combination
11/20/2013EP2663186A1 Lipid-lowering antidiabetic agent
11/20/2013EP2663185A1 Anti-obesity potential of calebin a
11/20/2013EP2531501B1 Apoptosis signal-regulating kinase 1 inhibitors
11/20/2013EP2529742B1 Pharmaceutical composition comprising dapagliflozin and cyclodextrin
11/20/2013EP2519521B1 Tetrahydrotriazolopyridine compounds as selective mglu5 receptor potentiators useful for the treatment of schizophrenia
11/20/2013EP2514750B1 Bromo-phenyl substituted thiazolyl dihydropyrimidines
11/20/2013EP2506831B1 Carboxyvinyl polymer-containing nanoparticle suspensions
11/20/2013EP2491024B1 Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
11/20/2013EP2490695B1 Method of preventing type 1 diabetes
11/20/2013EP2488523B1 N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
11/20/2013EP2480532B1 Piperidine derivatives and their use to treat obesity, diabetes, dyslipidemia and atherosclerosis
11/20/2013EP2441760B1 Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
11/20/2013EP2430022B1 1,2,4-Triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
11/20/2013EP2419432B1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
11/20/2013EP2414348B1 Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
11/20/2013EP2408740B1 Compounds for treating inflammation and pain
11/20/2013EP2407451B1 N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
11/20/2013EP2403832B1 N-(hetero)aryl,2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
11/20/2013EP2389226B1 Bridged and fused heterocyclic antidiabetic compounds
11/20/2013EP2365760B1 Novel compound containing vanillin and ethylvanillin, and preparation and applications thereof
11/20/2013EP2350022B1 New benzimidazole derivatives
11/20/2013EP2346834B1 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
11/20/2013EP2344130B9 Pharmaceutical topical compositions
11/20/2013EP2340022B1 Combination therapy for tuberculosis
11/20/2013EP2334672B1 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO
11/20/2013EP2320888B1 Laidlomycin compositions and methods
11/20/2013EP2310031B1 Combination of a tiliroside and lysine-valine 5 diaminohydroxybutyrate
11/20/2013EP2307387B1 Novel heterocyclyl compounds for treatment of cardiovascular disease
11/20/2013EP2303225B1 Compositions of Carbon Dioxide Adduct of Ertapenem and Polymorphic Forms of Ertapenem Monosodium Salt
11/20/2013EP2300452B1 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
11/20/2013EP2300437B1 Benzpyrazol derivatives as inhibitors of pi3 kinases
11/20/2013EP2285808B1 Spiro-indole derivatives for the treatment of parasitic diseases
11/20/2013EP2271621B1 Pyridyl derivatives as cftr modulators
11/20/2013EP2265616B1 Furo-and thieno[3,2-c]pyridines
11/20/2013EP2265599B1 Crystal form of phenylaminopyrimidine derivative
11/20/2013EP2252149B1 A method for the preparation of fentanyl
11/20/2013EP2251337B1 Dihydropyridine calcium antagonist compounds, preparation methods and medical uses thereof
11/20/2013EP2251014B1 Combinations of an anti-cancer agent and a cholestanol derivative
11/20/2013EP2246338B1 Novel catechol derivative, pharmaceutical composition containing the same, use of the catechol derivative, and use of the pharmaceutical composition
11/20/2013EP2240443B1 Proline analogs as ligands for cannabinoid receptors for the treatment of pain
11/20/2013EP2220029B1 Benzamide compounds and their use as prostaglandin E4 receptor agonists
11/20/2013EP2215047B1 Method of treating vitamin b12 deficiency
11/20/2013EP2214675B1 Process for making thienopyrimidine compounds
11/20/2013EP2205610B1 Thienopyrimidiene derivatives as pi3k inhibitors
11/20/2013EP2205072B1 Methods for treating a variety of diseases and conditions, and compounds useful therefor
11/20/2013EP2203478B1 Compositions and methods for use of antibodies against sclerostin
11/20/2013EP2202227B1 Novel histidine derivative
11/20/2013EP2200595B1 Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
11/20/2013EP2190849B1 4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
11/20/2013EP2146572B1 Bicyclic anilide heterocyclic cgrp receptor antagonists
11/20/2013EP2143429B1 Use of cilastatin to reduce the nephrotoxicity of different compounds
11/20/2013EP2125824B1 Improved preparation of oxymorphone from oripavine
11/20/2013EP2114409B1 Composition and method for treating or preventing skeletal muscle fibrosis
11/20/2013EP2112151B1 Haloaryl substituted aminopurines for use in treatment
11/20/2013EP2091943B1 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
11/20/2013EP2086972B1 Compounds modulating c-fms and/or c-kit activity and uses therefor
11/20/2013EP2085078B1 Controlled porosity osmotic pump tablet of high permeable drugs and the preparation method thereof
11/20/2013EP2075334B1 EG-VEGF nucleic acids and polypeptides and methods of use
11/20/2013EP2074989B1 Abuse resistance opioid transdermal delivery device
11/20/2013EP2036566B1 Use of 20(s)-protopanoxadiol in manufacture of antidepressants
11/20/2013EP1951708B1 Piperazine derivative useful as a ccr5 antagonist
11/20/2013EP1931350B1 Administration of dipeptidyl peptidase inhibitors
11/20/2013EP1915372B1 Indole derivatives as crth2 receptor antagonists
11/20/2013EP1904067B1 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
11/20/2013EP1881982B1 Imidazolone phenylalanine derivatives as vla-4 antagonists
11/20/2013EP1847244B1 Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same
11/20/2013EP1827412B1 Compositions for use in surgery
11/20/2013EP1809624B1 Pyrimidine sulphonamide derivatives as chemokine receptor modulators
11/20/2013EP1802579B1 Derivatives of 3-arylaminopyridine
11/20/2013EP1801108B9 Morpholine compounds for the treatment of inflammations
11/20/2013EP1781663B1 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament
11/20/2013EP1765805B1 Cgrp receptor antagonists
11/20/2013EP1709044B2 Oxazolidinone-quinolone hybrid antibiotics
11/20/2013EP1709009B1 6-amino-5-cyano-pyrimidine-4-ones used for improving perception, power of concentration, learning efficiency, and/or memory power
11/20/2013EP1690545B1 Preparation of Product R and product so obtained
11/20/2013EP1683520B1 Water-soluble prodrugs
11/20/2013EP1651762B1 Small interfering rna specific to sub-units alpha, alpha' and beta of the kinase protein ck2, and the applications of the same
11/20/2013EP1613628B1 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
11/20/2013EP1572199B1 Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
11/20/2013EP1567022B1 Sustained improver of muscular fatigue
11/20/2013EP1489082B1 Intermediate compounds
1 ... 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 ... 7860